Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
A diagnostic and therapeutic secreted target protein that is upregulated in a subset of human patients with Osteoarthritis. It is a strong regulatory candidate for the transformation of maintenance chondrocytes into digestive aggravators of OA. More
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
New pharmaceutical compositions for oral use containing diclofenac together with alkali metal carbonates and bicarbonates and particular flavouring substances. More
The present invention relates to osteoarthritis (OA) and methods of OA diagnosis and treatment via the findings of a genome-wide analysis of dysregulated genes in OA. More
The use of vitamin-drug formulations to (a) enable oral absorption of pharmaceutically active ingredients which are not normally absorbed in the GI tract and (b) enhance delivery of drugs to diseases such as cancer and rheumatoid arthritis. More
All rights reserved. Terms and Conditions | Contact us
